Treatment of Cardiac Arrhythmias During Pregnancy
Tóm tắt
Maternal and fetal arrhythmias occurring during pregnancy may jeopardise the life of the mother and the fetus. When arrhythmias are well tolerated and patients are minimally symptomatic, conservative therapy, such as observation and rest or vagal manoeuvres, should be employed. When arrhythmias cause debilitating symptoms or haemodynamic compromise, antiarrhythmic drug therapy is indicated. Although no antiarrhythmic drug is completely safe during pregnancy, most are well tolerated and can be given with relatively low risk. Physiological changes that occur during pregnancy mandate caution when administering antiarrhythmic drugs, with close monitoring of serum concentration and patient response. Drug therapy should be avoided during the first trimester of pregnancy if possible, and drugs with the longest record of safety should be used as first-line therapy. Several therapeutic options exist for most arrhythmias in the mother and fetus. Of the class IA agents, quinidine has the longest record of safety during pregnancy, and is generally well tolerated. Procainamide is also well tolerated, and should be a first line option for acute treatment of undiagnosed wide complex tachycardia. All IA agents should be administered in the hospital under cardiac monitoring due to the potential risk of ventricular arrhythmias (torsade de pointes). The IB agent, lidocaine (lignocaine), has local anaesthetic role but is also generally well tolerated as an antiarrhythmic agents. Phenytoin should be avoided due to the high risk of congenital malformations and limited role as an antiar-rhythmic drug. Of the IC agents, flecainide has been shown to be very effective in treating fetal supraventricular tachycardia complicated by hydrops. β-Blockers are generally well tolerated and can be used with relative safety in pregnancy, although recent data suggest that they may cause intrauterine growth retardation if they are administered during the first trimester. Amiodarone, a class II agents with characteristics of the other antiarrhythmic drug classes, has been reported to cause congenital abnormalities; it should be avoided during the first trimester and used only to treat life-threatening arrhythmias that fail to respond to other therapies. Adenosine is generally safe to use in pregnancy, and is the drug of choice for acute termination of maternal supraventricular tachycardia. Digoxin has a long track record of treating both maternal and fetal arrhythmias, and is one of the safest antiarrhythmics to use during pregnancy. Direct current cardioversion to terminate maternal arrhythmias is well tolerated and effective, and should not be delayed if indicated. The use of an implantable cardioverter-defibrillator should be considered for women of childbearing potential with life-threatening ventricular arrhythmias.
Tài liệu tham khảo
Saxon LA, Perloff JK. Arrhythmias and conduction disturbances associated with pregnancy. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmia. Baltimore (MD): Williams & Wilkins, 1995: 1161–74
Ostrzega E, Mehra A, Widerhorn J, et al. Evidence of increased incidence of arrhythmias during pregnancy: a study of 104 pregnant women with symptoms of palpitations, dizziness or syncope [abstract]. J Am Coll Cardiol 1992; 19: 125A
Widerhorn J, Widehorn ALM, Rahimtoola SH, et al. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 1992; 123: 796–8
Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36: 137–78
Rotmensch HH, Elkayam U, Frishman W. Antiarrhythmic drug therapy during pregnancy. Ann Intern Med 1983; 98: 487–97
Berlin CM. Pharmacologic considerations of drug use in the lactating mother. Obstet Gynecol 1981; 58 Suppl.: 17s–23s
Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137–50
Drugs facts and comparisons. St. Louis (MO): Facts and Comparisons, 1997
Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129–47
Meyer J, Lackner JE, Schochet SS. Paroxysmal tachycardia in pregnancy. Am Heart J 1931; 94: 1901–4
Hill LM, Malkasian GD. The use of quinidine sulfate throughout pregnancy. Obstet Gynecol 1979; 54: 366–8
Wladimiroff JW, Stewart A. Treatment of fetal cardiac arrhythmias. Br J Hosp Med 1985; 34: 134–40
Allen NM, Page RL. Procainamide administration during pregnancy. Clin Pharm 1993; 12: 58–60
Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995; 130: 871–6
Schnider SM. Choice of anesthesia for labor and delivery. Obstet Gynecol 1981; 58: S24–S34
Martin LV, Jurand A. The absence of teratogenic effects of some analgesics use in anesthesia: additional evidence from a mouse model. Anaesthesia 1992; 47: 473–6
Brown WU, Bell GC, Alper MH. Acidosis, local anesthesia and the newborn. Obstet Gynecol 1976; 48: 27–30
Gregg AR, Tomich PG. Mexiletene use in pregnancy. J Perinatol 1988; 8: 33–5
Timmis AD, Jackson G, Holt DW. Mexiletine for control of ventricular dysrhythmias during pregnancy. Lancet 1980; II: 647–8
Lowes HE, Ives TJ. Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol 1987; 157: 446–7
Atkinson AJ Jr, Davison R. Diphenylhydantoin as an antiarrhythmic drug. Ann Rev Med 1974; 25: 99–113
Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risk of the offspring of women treated with hydantoin anticonvulsants with emphasis on fetal hydantoin syndrome. J Pediatr 1976; 89: 662–8
Echt DS, Liebson PR, Mitchel B, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991; 324: 781–8
Allan LD, Chita SK, Sharland GK, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J 1991; 65: 46–8
Frohn-Mulder IM, Stewart PA, Witsenburg M, et al. The efficacy of flecainide versus digoxin in the management of fetal supaventricular tachycardia. Prenat Diagn 1995; 15: 1297–302
Vanderhalt AL, Cocjin J, Santulli TV, et al. Conjugated hyprbilirubenemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops. J Pediatr 1995; 126: 988–90
Capucci A, Boriani G. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. Drug Saf 1995; 12: 55–72
Frishman WH, Chesner M. Beta-adrenergic blockers in pregnancy. Am Heart J 1988; 115: 147–52
Pruyn SC, Phelan JP, Buchanan GC. Long-term propanolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol 1979; 135: 485–9
Rubin PC, Butters L, Clark DM, et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1983; 2: 431–4
Wichman K, Ryulden G, Karberg BE. A placebo controlled trial of metropolol in the treatment of hypertension in pregnancy. Scand J Clin Lab Invest 1984; 169: 90–4
Lip GYH, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol 1997; 79: 1436–8
Liedholm H, Melander A, Bitzen P-O, et al. Accumulation of atenolol and metoprolol in human breast milk. Eur J Clin Pharmacol 1971; 20: 229–31
Delvin RG, Duchin KL, Fleiss PM. Nadolol in human serum and breast milk. Br J Clin Pharmacol 1981; 12: 393–6
Schimimmel MS, Eldelman AJ, Wilschanski MA, et al. Toxic effects of atenolol consumed during breast feeding. J Pediatr 1989; 114: 476–8
Widerhorn J, Bhandari AK, Bughi S, et al. Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy. Am Heart J 1991; 22: 1162–5
De Wolf D, De Schepper J, Verhaaren H, et al. Congenital hypothyroid goiter and amiodarone. Acta Paediatr Scand 1988; 77: 616–8
Magee LA, Downar E, Sermer M, et al. Pregnancy outcome after gestational exposure to amiodarone in canada. Am J Obstet Gynecol 1995; 172: 1307–11
Ovadia M, Mitermayer B, Gifford L, et al. Human experience with amiodarone in the embrionic period. Am J Cardiol 1994; 73: 316–7
Strunge P, Frandsen J, Andeasen F. Amiodarone during pregnancy. Eur Heart J 1988; 9: 106–9
McKenna WJ, Harris L, Rowland E, et al. Amiodarone therapy during pregnancy. Am J Cardiol 1983; 51: 1231–3
Anderson, JL. Sotalol, bretylium, and other class 3 antiarrhythmics. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmia. Baltimore: Williams & Wilkins, 1995: 450-66
O’Hare MF, Murnaghan GA, Russell CJ, et al. Sotalol as a hypotensive agent in pregnancy. Br J Obstet Gynaecol 1980; 87: 814–20
Wagner X, Jouglard J, Moulin M, et al. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human milk. Am Heart J 1990; 119: 700–2
Kowey PR, Vander Lugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996; 78(8a): 46–52
Bryerly WG, Hartmann A, Foster DE, et al. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20: 552–4
Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal supraventricular tachyarrhythmias. J Clin Ultrasound 1985; 13: 265–73
Camm AJ, Garrat CJ. Adenosine and supraventricular tachycardia. N Engl J Med 1991; 325: 1621–9
Jaqueti J, Martinez-Hernandez D, Hernandez-Garcia R, et al. Adenosine deaminase in pregnant serum. Clin Chem 1990; 36: 2144
Mariani PJ. Pharmacotherapy of pregnancy-related SVT [letter]. Ann Emerg Med 1992; 21: 229
Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol 1995; 75: 521–3
Mason BA, Ogjunyemi D, Punla O, et al. Maternal and fetal cardiorespiratory responses to adenosine in sheep. Am J Obstet Gynecol 1993; 168: 1558–61
Page RL. Arrhythmias during pregnancy. Cardiac Electrophysiol Rev 1997; 1: 278–82
Chan V, Tse TF, Wong V. Transfer of digoxin across the placenta and into breast milk. Br J Obstet Gynaecol 1978; 85: 605–9
Rogers MC, Willerson JT, Goldblatt A, et al. Serum digoxin concentrations in the fetus, neonate and infant. N Engl J Med 1972; 287: 1010–3
Kerenyi TD, Gleicher N, Meller J, et al. Transplacental cardioversion of intrauterine supraventricular tachycardia with digitalis. Lancet 1980; 2: 393–5
King CR, Mattioli L, Goertz KK, et al. Successful treatment of fetal supraventricular tachycardia with maternal digoxin therapy. Chest 1984; 85: 573–5
Szekely P, Julian DG. Heart disease and pregnancy. Curr Probl Cardiol 1979; 4: 1–74
Parilla B, Strasburger JF, Socol ML. Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy. Am J Perinatol 1996; 13: 483–6
Mitani GM, Harrison EC, Steingberg I, et al. Digitalis glycosides in pregnancy. In: Elkayam U, Gleicher N, editors. Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. New York: Liss, 1990: 417–27
Gonzalez AR, Phelps SJ, Cochran EB, et al. Digoxin-like immunoreactive substance in pregnancy. Am J Obstet Gynecol 1987; 157: 660–4
Rosemond RL. Cardioversion during pregnancy. JAMA 1993; 269: 3167
Finlay AY, Edmonds V.D.C. cardioversion in pregnancy. Br J Clin Pract 1979; 33: 88–94
Klepper I. Cardioversion in late pregnancy. Anesthesia 1981; 36: 611–6
DeSilva RA, Graboys TB, Podrid PJ, et al. Cardioversion and defibrillation. Am Heart J 1980; 100: 881–95
Piper JM, Berkus M, Ridgeway LE III. Pregnancy complicated by chronic cardiomyopathy and an automatic implantable cardioverter defibrillator. Am J Obstet Gynecol 1992; 167: 506–7
Lee RV, Rodgers BD, White LM, et al. Cardiopulmonary resuscitation of pregnant women. Am J Med 1986; 81: 311–8
Rees GAD, Willis BA. Resuscitation in pregnancy. In: Evans TR, editor. ABC of resuscitation. 2nd ed. London: BMJ 1990: 50–3
Perkins V. CPR during pregnancy [letter]. Am Heart J 1995; 132: 1319
Page RL. CPR during pregnancy [letter]. Am Heart J 1995; 132: 1319